XW033NAIntroduction of Tarlatamab-dlle Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 10

New Technology›Anatomical Regions›Introduction

Billable / Specific Code

ICD-10-PCS XW033NA

CMS Source: FY 2026 ICD-10-PCS dataset. Effective Oct 1, 2025 – Sep 30, 2026.

XW033NA is a billable ICD-10-PCS procedure code for Introduction of Tarlatamab-dlle Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 10. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026). The root operation Introduction involves putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products.

Code Identity

ICD-10-PCS Code

XW033NA

Billable Status

Yes — Valid for Submission

Code Describes

Introduction of Tarlatamab-dlle Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 10

Parent Code

XW0

Short Description

Introduce Tarlatamab-dlle in Periph Vein, Perc, New Tech 10

PCS Table Breakdown

Each ICD-10-PCS code is built from seven characters, each an axis of the procedure. Hover or tap the icons for the official CMS definitions.

Position	Designation	Value	Meaning
1	Section	X	New Technology
2	Body System	W	Anatomical Regions
3	Operation	0	Introduction
4	BodyPart	3	Peripheral Vein
5	Approach	3	Percutaneous
6	Device/Substance/Technology	N	Tarlatamab-dlle Antineoplastic
7	Qualifier	A	New Technology Group 10

Code History

Replaces previously assigned code(s):

3E03305 — Introduce Oth Antineoplastic in Periph Vein, Perc

Similar Procedure Codes

Filter related codes list:

Questions About XW033NA

Is XW033NA a billable code?

Yes. XW033NA is a complete seven-character ICD-10-PCS code, specific enough to report Introduction of Tarlatamab-dlle Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 10 on inpatient claims from October 1, 2025 through September 30, 2026.

What do the characters in XW033NA mean?

XW033NA breaks down character by character: the 1st character X is the Section (New Technology); the 2nd character W is the Body System (Anatomical Regions); the 3rd character 0 is the Operation (Introduction); the 4th character 3 is the BodyPart (Peripheral Vein); the 5th character 3 is the Approach (Percutaneous); the 6th character N is the Device/Substance/Technology (Tarlatamab-dlle Antineoplastic); the 7th character A is the Qualifier (New Technology Group 10).